Aethlon Medical Schedules Fiscal Year End Results and Conference Call for June 10, 2026
Event summary
- Aethlon Medical will release fiscal year-end financial results on June 10, 2026, at 4:15 p.m. ET.
- A conference call to review financial results and corporate developments will follow at 4:30 p.m. ET.
- The Hemopurifier, Aethlon's clinical-stage device, has FDA Breakthrough Device designation for cancer and viral infections.
- The company focuses on developing therapies for cancer and life-threatening infectious diseases.
The big picture
Aethlon Medical's upcoming financial results and conference call come at a critical juncture as it navigates the regulatory pathway for its Hemopurifier device. The company's focus on cancer and infectious disease therapies aligns with growing demand for innovative immunotherapeutic solutions. Success hinges on securing FDA approvals and demonstrating clinical efficacy in high-unmet-need indications.
What we're watching
- Regulatory Progress
- The pace at which the Hemopurifier advances through FDA approvals will determine its market viability.
- Financial Performance
- Whether Aethlon can demonstrate sustainable revenue growth amid clinical development costs.
- Clinical Trials
- How upcoming trial results will impact investor confidence and potential partnerships.
Related topics